Search clinical trials for: BI 1584862

Total 1215 results

Fondazione del Piemonte per l'Oncologia

Completed

Comparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer

Prostatic Neoplasm

Italy
AbbVie

Completed

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Psoriatic Arthritis
Boehringer Ingelheim

Completed

Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers

Healthy
BioInvent International AB

Completed

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Multiple Myeloma

Denmark, Belgium, United States, Sweden
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Healthy | Arthritis, Rheumatoid

Germany, Netherlands, New Zealand, Poland, Spain, Czechia
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

Healthy
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/79b Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute

Recruiting

CD19/70 Bi-specific CAR-T Cell Therapy

B Cell Malignancies

China
China National Center for Cardiovascular Diseases

Recruiting

Bi-atrial Versus Left Atrial Ablation for Patients With Rheumatic Mitral Valve Disease and Non-paroxysmal Atrial Fibrillation

Persistent Atrial Fibrillation

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Denmark, France, Ireland, Korea, Republic of, Portugal, United Kingdom
Presidio Pharmaceuticals, Inc.
Boehringer Ingelheim

Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
National Taiwan University Hospital
Ministry of Science and Technology, Taiwan; National Health Research Institutes...

Recruiting

Proximal Priority Versus Distal Priority Robotic Priming Effects in Patients With Chronic Stroke

Stroke

Taiwan
BioInvent International AB

Terminated

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Sweden
AbbVie
Boehringer Ingelheim

Completed

Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Medtronic Bakken Research Center

Completed

ConsultaTM CRT-D Clinical Evaluation Study

Heart Failure | Ventricular Dysfunction | Tachyarrhythmias

Germany
University of Dundee
Abbott Medical Devices; Chest, Heart and Stroke Association Scotland

Completed

Choosing the Right Pacing Mode in Heart Failure - The CHOICE Trial (CHOICE)

Heart Failure

United Kingdom
Boehringer Ingelheim

Completed

Phase II Study of BI 2536 in Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

Healthy

Germany
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Healthy
First Affiliated Hospital of Wenzhou Medical University
Shanghai Zhongshan Hospital; Shanghai 10th People's Hospital; The Affiliated... and other collaborators

Not yet recruiting

Safety and Effectiveness of Left Bundle Branch Pacing in Patients With Cardiac Dysfunction and AV Block

Heart Failure | Atrioventricular Block, Second and Third Degree | Left Bundle Branch Pacing

China
The First Affiliated Hospital of Shanxi Medical...

Completed

Assessment of a Novel Tracheostomy Tie (AONTT)

Tracheostomy Complication

China
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Biosense Webster, Inc.

Recruiting

A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator (Omny-IRE)

Atrial Fibrillation

Belgium, Canada, Netherlands, Italy, Lithuania, Croatia, Germany, Czechia
Boehringer Ingelheim

Completed

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency

Germany
Boehringer Ingelheim
IQVIA global CRO

Completed

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Philogen S.p.A.
Boehringer Ingelheim

Completed

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (PHIBI)

Acute Myeloid Leukemia (AML) Relapse

Germany
AbbVie
Boehringer Ingelheim

Completed

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis
Kowa Research Institute, Inc.

Completed

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100 (OCT)

Glaucoma | Healthy | Retinal Disease

United States
Centre Hospitalier Universitaire de Nīmes
Direx Systems GmbH

Withdrawn

Low Frequency Shock Wave Therapy for Improving Post-prostatectomy Erectile Dysfunction: a Prospective Pilot Study (ProstaChoc 1)

Erectile Dysfunction

France
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Liver Cirrhosis | Hepatitis C

Germany
Wang Joon Ho

Not yet recruiting

Comparison of Kinematic Movements Between ACL Deficiency With ACL Reconstruction and Healthy People

Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Reconstruction | Healthy People

Korea, Republic of
Boehringer Ingelheim
Zealand Pharma

Completed

A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

Liver Diseases | Healthy | Obesity

Germany, United States, Hungary, New Zealand, Slovakia, Poland
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
Oxford University Hospitals NHS Trust

Completed

Biatrial Global High-density Electroanatomical Mapping of Atrial Fibrillation (BiMap-AF)

Atrial Fibrillation

United Kingdom
Boehringer Ingelheim

Recruiting

A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems

Liver Diseases | Healthy

United States
Boehringer Ingelheim

Terminated

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Macular Degeneration

United Kingdom, United States
University of Chicago
CHEST Foundation

Completed

Virtual Teach-to-Goal Education vs. Brief Education for Children (V-TTG vs BI)

Asthma | Shortness of Breath | Bronchospasm

United States
Medtronic Cardiac Rhythm and Heart Failure

Completed

Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications

Heart Failure

China
Brigham and Women's Hospital
Massachusetts General Hospital

Withdrawn

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

Chronic Obstructive Airway Disease

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors

Spain, Canada, United States, Sweden
Boehringer Ingelheim

Terminated

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Purpura, Thrombocytopenic, Idiopathic

United States

3

Subscribe